Dept Medical Oncology, Gestational Trophoblastic Disease Centre, Charing Cross Hospital Campus of Imperial College London, Fulham Palace Rd, London W68RF, UK.
Dept Medical Oncology, Gestational Trophoblastic Disease Centre, Charing Cross Hospital Campus of Imperial College London, Fulham Palace Rd, London W68RF, UK.
Best Pract Res Clin Obstet Gynaecol. 2021 Jul;74:159-167. doi: 10.1016/j.bpobgyn.2021.05.006. Epub 2021 May 25.
Considerable differences exist in the management of gestational trophoblastic disease (GTD) both nationally and internationally despite numerous efforts to harmonise patient care. This partly reflects differences in healthcare systems and availability of resources. However, even in first world equivalent economies with similar healthcare systems differences remain, which appear to impact survival. Recently, new international guidelines have been established in Europe through a series of consensus meetings. Improvement of outcomes will depend on the establishment of dedicated centres with appropriate patient pathways according to these guidelines. This review will highlight some of the differences and efforts to unify the management of GTD across the globe and discuss areas for future development.
尽管在协调患者护理方面做出了许多努力，但妊娠滋养细胞疾病（GTD）的管理在国内外仍存在很大差异。这在一定程度上反映了医疗保健系统和资源可用性的差异。然而，即使在具有相似医疗保健系统的发达国家中，差异仍然存在，这似乎对生存率产生了影响。最近，通过一系列共识会议，在欧洲制定了新的国际指南。根据这些指南，建立专门的中心并制定适当的患者途径将有助于改善治疗效果。本文将重点介绍全球妊娠滋养细胞疾病管理方面的差异和统一努力，并讨论未来的发展方向。
